Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522935 · ClinicalTrials.gov registry record · Phase 1
Subcutaneous Elafin in Healthy Subjects
A Phase 1 study of Pulmonary Arterial Hypertension, sponsored by Roham T. Zamanian.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03522935 is a Phase 1 study of Pulmonary Arterial Hypertension that has completed, run by Roham T. Zamanian. The registered enrollment target is 30 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03522935, a Phase 1 study of Pulmonary Arterial Hypertension, has completed, sponsored by Roham T. Zamanian.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects. The purpose of this study is to assess Elafin that is being developed for treatment of PAH. Elafin inhibits elastase, an enzyme that is increased in pulmonary hypertension and is a major factor in the development of PAH. Elafin will be administered subcutaneously daily for 7 days in normal healthy subjects followed over a 28 day time period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Elafin
Study Locations (1)
North Carolina
- Duke Early Phase Research Unit (DEPRU) - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522935
The ClinicalTrials.gov registry entry for NCT03522935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is Roham T. Zamanian, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03522935 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03522935 about?
NCT03522935 is a clinical study titled "Subcutaneous Elafin in Healthy Subjects". A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects. The purpose of this study is to assess Elafin that is being developed for treatment of PAH. Elafin inhibits...
What is the current status of trial NCT03522935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-03-18. Estimated completion is 2020-11-18.
What conditions does trial NCT03522935 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT03522935?
The interventions under investigation include: Placebo (DRUG), Elafin (DRUG).
Who is sponsoring clinical trial NCT03522935?
This trial is sponsored by Roham T. Zamanian, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03522935 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 1
-
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 1
-
A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
COMPLETED · Phase 1
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.